Cardiac Biomarkers

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. Industry Review

• Cardiovascular Diseases: Leading cause of Mortality Worldwide
• Table 1: Region-wise Incidence & Prevalence of Cardiovascular Diseases in 2006
• Basic Topologies of Cardiovascular Diseases
• Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs
• Cardiac Biomarkers - Making Diagnosis Easier and Quicker
• What is a Cardiac Marker:
• Necessity of a Cardiac Marker Assay Test
• How it works?
• Major Cardiac Markers and their Properties
• Market Analysis
• Market Trends
• Strong Demand for Risk Assessment Markers
• Intense Competition among Players in the Cardiac Diagnostics Market
• The Future of Cardiac Marker POCT Segment
• Need for Early Detection Markers
• Rapid Turnaround time: A Crucial Parameter for POC Testing Kits

2. Competitive Analysis

• Siemens Healthcare becomes the leader, after a series of Acquisitions
• Product Portfolio of Bayer and Dade Behring

3. Cardiac Markers and Myocardial Infarction

• Chain Reaction After an Event of MI
• Action Plan after an Event of MI
• Protocol for Conducting AMI Markers Tests
• Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
• Creatine Kinase - The Traditional Gold Standard, Loosing Sheen
• Market and Forecasts:
• Isomers
• Kinetics
• Purpose of Test and When to Order
• Evaluation
• Points to remember
• Cardiac Troponin - Taking Over from CK-MB
• Market and Forecast
• Overview
• Troponin Tissue-Specific Subtypes
• Other Diseases
• Uses of Troponin Tests
• New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
• Myoglobin
• Purpose of Test and When to Order
• Testing and Evaluation
• Points to Remember
• Market and Forecast

4. Cardiac Markers and Congestive

• Key Facts
• BNP (B-type Natriuretic Peptide)
• NT-proBNP (N-terminal proBNP)
• Purpose of Tests and When to Order
• Testing and Evaluation
• Points to Remember
• Market and Forecast
• Market Characteristics
• Choosing the Right BNP and NT proBNP Assay Kit in the Market
• Evolution of BNP and NT proBNP Market
• NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function

5. Stroke Biomarkers - A Review

• Player Initiatives
• Other Important Cardiac Biomarkers
• Homocysteine
• C-Reactive Protein
• Plasminogen Activator Inhibitor-1
• D-Dimer
• Thrombus Precursor Protein
• Potential Future Cardiac Biomarkers

6. Cardiac Biomarker Testing in Clinical

• Market and Forecast
• Leading Players in Laboratory Cardiac Markers

7. Cardiac Biomarkers at Point-of-Care Testing

• Market and Forecast
• Major Players Operating in the Cardiac Markers POCT Segment
• Cardiac Markers Point-of-Care testing (POCT) Segment: Major Players & Their Operating Brands.

8. Strategic Corporate Developments

• Response Biomedical Signs Partnership Agreement with Roche
• Nanogen and Elitech Plans to Merge
• Compugen Announces Discovery of Troponin I Biomarker Variant, Inks Agreement with Biosite
• Inverness Acquires Biosite
• Siemens Acquires Diagnostic Division of Bayer Healthcare
• Siemens Announces Acquisition of Dade Behring
• Beckman Collaborates in CVD Related Research Projects
• Dade Behring Receives Sublicense to New Cardiac Marker
• Inverness Acquires Cholestech
• Response Biomedical Secures Clearance to Market RAMP(r) NT-proBNP Test
• Acrongenomics Collaborates with Molecular Vision and Pearson Matthews
• BG Medicine Obtains Rights to Develop Tests for Congestive Heart Failure
• Nanogen Gains US Reissue Patent for Combined Use of Biomarkers for CHF Diagnosis
• Nanogen Secures FDA Approval for CHF NT-proBNP EDTA Plasma Test
• Roche Diagnostics Secures FDA Approval for Roche Elecsys(r) proBNP Test
• Nanogen Acquires Rapid Cardiac Immunoassay Test Businesses of SDI
• Response Biomedical Starts Clinical Trials of the RAMP NT- proBNP Test
• Procter and Gamble, Inverness to Form JV for Consumer Diagnostics
• Roche Diagnostics Grants Rights for NT- proBNP to Mitsubishi Kagaku Latron
• Bayer Healthcare Receives FDA Approval for Troponin-I-Test Tnl-Ultra
• MKI Obtains EU Approval and CE Mark for Four Cardiac Markers
• Dade Behring Grants PIGF Rights to Abbott
• OXIS International Acquires Biocheck
• Wampole, Roche collaborate on Ischemia Modified Albumin Test
• Nanogen Extends Point-of-Care Diagnostic Tests Distribution in Europe
• Abbott, Cleveland Clinic Agrees to Develop MPO Cardiac Test
• Response Biomedical Receives Non-exclusive Rights to Roche' s Cardiac Markers
• Roche Diagnostics Grants Rights to Response Biomedical for Troponin T and NT- proBNP
• Inverness to Acquire Ischemia Technologies
• Roche Diagnostics Grants Rights for NT- proBNP to bioMerieux
• Roche Confers Rights of NT-proBNP to Ortho-Clinical Diagnostics
• Dade Behring Grants CRP Sublicense to Roche Diagnostics
• Roche Awards Non Exclusive Rights of NT-proBNP marker to DPC
• Abbott Gains Approval for CK-MB Test in the US
• i-STAT Gains Approval for Troponin I Test from US FDA

9. Product Launches/Developments/Approvals

• Response Bags FDA Clearance for RAMP(r) NT-proBNP Test
• bioMerieux Rolls out VIDAS(r) NT-proBNP
• Roche Diagnostics Introduces Cobas-H-232 Handheld Cardiac Marker System
• OXIS Discovers a Unique Diagnostic Biomarker for Cardiovascular Disease
• Ortho-Clinical Presents Sensitivity Troponin I Test, VITROS Troponin I ES
• bioMerieux Unveils ' VIDAS(r) Troponin I Ultra'
• Roche Elecsys proBNP Assay Secures FDA Clearance
• Bayer Launches New Tnl-Ultra(tm) Troponin Assay on ADVIA Centaur(r) CP Immunoassay system
• Ortho-Clinical Diagnostics Receives FDA Clearance for VITROS NT-proBNP Assay
• Dade Behring Launches CardioPhase(r) hsCRP Test
• Diagnostic Products Corporation to Market NT-proBNP Outside US
• Dade Behring Introduces Homocysteine Assay for BN(tm) System
• Biosite Develops Triage(r) Cardio ProfilER(tm) Panel
• A Breakthrough Biochip Array System for MI
• FDA Approves Emergency Department Diagnostic Test from Biosite
• Response Biomedical Obtains Regulatory Clearance for RAMP(r)
• Response Biomedical Gains US FDA Approval for 3rd RAMP(r) Test
• CLINIQA Rolls Out Liquid Stable Cardiac Marker Controls
• Abbott Releases AxSYM(r) Troponin-I ADV Assay in World Markets

10. Focus on Select Global Players

• Abbott Diagnostics (USA)
• Ani Biotech Oy (Finland)
• Axis-Shield PoC (UK)
• Beckman Coulter, Inc. (USA)
• biomerieux (France)
• Inverness Medical Innovations, Inc. (USA)
• LifeSign LLC (USA)
• Nanogen Inc. (USA)
• Ortho-Clinical Diagnostics, Inc. (USA)
• Oxis International, Inc. (USA)
• Prognostix, Inc. (USA)
• Response Biomedical Corp. (Canada)
• Roche Diagnostics Corp. (USA)
• Siemens Healthcare Diagnostics, Inc. (USA)

11. Global Market Perspective

• Table 2: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 3: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 4: World 10-Year Perspective for Cardiac Biomarkers by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 5: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 6: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 7: World 10-Year Perspective for Cardiac Biomarkers in Laboratory Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 9: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Cardiac Biomarkers in Point-of-Care Testing Sector by Geographic Region - US, Europe, and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for CK-MB Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 12: World Historic Review Analysis for CK-MB Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for CK-MB Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Analysis for Cardiac Troponin Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 15: World Historic Review Analysis for Cardiac Troponin Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Cardiac Troponin Assay Test by Geographic Region- USA, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Analysis for Myoglobin Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 18: World Historic Review Analysis for Myoglobin Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Myoglobin Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Analysis for BNP & NT-proBNP Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 21: World Historic Review Analysis for BNP & NT-proBNP Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for BNP & NT-proBNP Assay Test by Geographic Region- US, Europe and Rest of the World Markets. Independently Analyzed with Annual Sales Figures in US$ million for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Cardiovascular Diseases in US: A Review
  • Table 23: The US Disease Statistics for Coronary Heart Disease (CHD) & Myocardial Infarction (MI)
  • Table 24: The US Prevalence of Coronary Heart Disease (CHD) as a Percentage of Total Population by Age-group & Sex, in 2005 - 06. (includes corresponding Graph/Chart)
  • Table 25: The US Annual Number of New & Recurrent Adults diagnosed with Heart Attack by Age & Sex in the Recent Past (includes corresponding Graph/Chart)
  • Table 26: The US Disease Statistics for Heart Failure
  • Table 27: The Annual Number of Americans Diagnosed with Heart Failure as ' per 1000 persons' by Age & Sex, in the Recent Past (includes corresponding Graph/Chart)
  • 30% Fall in Number of Deaths due to Heart Diseases & Strokes Over Last Decade
  • Senior Citizens at High Risk for Heart Failure
  • CHF Biomarkers to Spearhead the US market
  • US Cardiac Markers POCT Segment
  • Table 28: US AMI (Acute Myocardial Infarction) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart)
  • Table 29: US CHF (Congestive Heart Failure) Diagnostics Market: Market Share by Revenue held by Major Players (Dade Behring, Beckman Coulter, Bayer Diagnostics, and Others) in 2006 (includes corresponding Graph/Chart)
  • Table 30: US Laboratory Testing Segment: Market Share by Revenue held by Major Players (Abbott, Dade Behring, Bayer, Beckman Coulter, Roche, Ortho-clinical, and Others) in 2001 (includes corresponding Graph/Chart)
  • Product Launches/Approvals/Developments
  • Strategic Corporate Developments
  • Key Players
  • Abbott Diagnostics
  • Beckman Coulter, Inc.
  • diaDexus, Inc.
  • Inverness Medical Innovations, Inc.
  • LifeSign LLC
  • Nanogen Inc.
  • Ortho-Clinical Diagnostics, Inc.
  • Oxis International, Inc.
  • Prognostix, Inc.
  • Roche Diagnostics Corp.
  • Siemens Healthcare Diagnostics, Inc.
• B. Market Analytics
  • Table 31: US Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 32: US Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 33: US 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015
  • Table 34: US Recent Past, Current and Future Analysis for Cardiac Markers by Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 35: US Historic Review Analysis for Cardiac Markers by Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 36: US 10-Year Perspective for Cardiac Markers by Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart)

2. Europe

• A. Market Analysis
  • European Cardiovascular Diseases Fact Sheet
  • Evolution of the European Cardiac Risk Markers Market
  • Cardiac Markers in Primary Care Sector
  • Product Launches/Approvals/Developments
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 37: European Recent Past, Current and Future Analysis for Cardiac Markers by Region - France, Germany, Italy, UK, and ' Rest of Europe' Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 38: European Historic Review Analysis for Cardiac Markers by Region - France, Germany, Italy, UK, and ' Rest of Europe' Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 39: European 10-Year Perspective for Cardiac Markers by Region - France, Germany, Italy, UK, and ' Rest of Europe' Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart)
  • Table 40: European Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 41: European Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 42: European 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015
  • Table 43: European Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 44: European Historic Review Analysis for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 45: European 10-Year Perspective for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart)

2a. France

• A. Market Analysis
  • Product Launches/Approvals/Developments
  • Strategic Corporate Developments
  • Key Players
• B. Market Analytics
  • Table 46: French Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 47: French Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 48: French 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015

2b. Germany

• A. Market Analysis
  • Rennesens GmbH
• B. Market Analytics
  • Table 49: German Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 50: German Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 51: German 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015.

2c. Italy

• Market Analysis
• Table 52: Italian Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
• Table 53: Italian Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
• Table 54: Italian 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of- Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015

2d. United Kingdom

• A. Market Analysis
  • UK Cardiovascular Diseases Fact Sheet
  • Table 55: The UK' s Healthcare Costs of Cardio Vascular Diseases (CVD), Coronary Heart Diseases (CHD) & Strokes in 2006 (includes corresponding Graph/Chart)
  • Siemens and PETNET Pharmaceuticals Acquire PETNET' s New England Operations
  • Key Players
  • Axis-Shield PoC
• B. Market Analytics
  • Table 56: UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 57: UK Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 58: UK 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015

2e. Rest of Europe

• A. Market Analysis
  • Key Player
  • Ani Biotech Oy
• B. Market Analytics
  • Table 59: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 60: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 61: Rest of Europe 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015

3. Rest of the World

• A. Market Analysis
  • Evolution of BNP Test market in Japan
  • Product Launches/Approvals/Developments
  • Strategic Corporate Developments
  • Key Players
  • Response Biomedical Corporation (Canada)
  • Sekisui Medical Co. Ltd. (Japan)
  • Shionogi and Co. Ltd. (Japan)
• B. Market Analytics
  • Table 62: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 63: Rest of the World Historic Review Analysis for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 64: Rest of the World 10-Year Perspective for Cardiac Markers by Segment - Clinical Laboratory testing and Point-of-Care Testing (POCT) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015
  • Table 65: Rest of the World Recent Past, Current and Future Analysis for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2006 through 2015 (includes corresponding Graph/Chart)
  • Table 66: Rest of the World Historic Review Analysis for Cardiac Markers by Assay Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for Years 2001 through 2005 (includes corresponding Graph/Chart)
  • Table 67: Rest of the World 10-Year Perspective for Cardiac Markers by Test Type - AMI (CK-MB, Cardiac Troponin and Myoglobin), and CHF (BNP and NT proBNP) Markets: Independently Analyzed with Annual Sales in US$ million for 2006, 2009 and 2015 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE